CAMBRIDGE, MA, UNITED STATES, May 18, 2026 /EINPresswire.com/ -- EyeCool Therapeutics today announced the publication ...

First-line camrelizumab plus chemotherapy in patients with advanced non-squamous non-small cell lung cancer: A nationwide, retrospective real-world study. This is an ASCO Meeting Abstract from the ...

Treatment patterns and outcomes of head and neck cancer in sub-Saharan Africa: Insights from a multi-institutional cancer dataset. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I.

Biomarker testing identifies high-risk early-stage NSCLC patients for adjuvant chemotherapy, reducing recurrence risk by 78%. The AIM-HIGH study shows a 96% disease-free survival rate at 24 months ...

Q1 2026 Management View Dr. Jennifer Buell (Co-Founder, President, CEO & Director) framed recent disclosures around clinical and mechanistic readouts across oncology and pulmonary indications, saying, ...

A meta-analysis of randomized controlled trials testing the effects of social-media-based mental health interventions found ...

A longitudinal, relationship-based case management approach significantly reduced health care costs and improved quality of life for Medicaid enrollees with complex needs over 1 year. Objectives: This ...

Final results from a landmark EORTC randomized trial with more than 20 years of follow-up show that irradiation of the ...

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: Receive the the ...

A recent double-blind, randomized trial highlights that adding dexamethasone to pectoral nerve (PECS) blocks for mastectomy ...